Han syftar på den kliniska Fas I/II-studien med Immunicums huvudprodukt ilixadencel. Med utgångspunkt i de positiva resultaten hos den första

New CEO shares vision for Immunicum. With such deal making experience, Sven Rohmann is a welcome addition to the Immunicum team as the company moves forward with ilixadencel in clinical trials and continues its plans for partnering. BioStock was able to get in touch with the new CEO and ask him about his plans for the company.

In December 2020 , Immunicum announced that it received Fast Track Designation from the FDA for ilixadencel in Gastrointestinal Stromal Tumors (GIST) and Orphan Drug Designation by the FDA for ilixadencel in hepatocellular carcinomas. Innovation in immuno-oncology. On Wednesday, November 18th Immunicum and DCprime combined forces to establish the company as a leader in cell-based cancer immunotherapies. . Click here to view the full announcement: https://bit.ly/35N Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders.

Immunicum ilixadencel

Ilixadencel is a cell-based, off-the-shelf immune primer, for the treatment of the orphan indication, Gastrointestinal Stromal Tumors (GIST). Ilixadencel is a pro-inflammatory allogeneic dendritic cell vaccine, being developed by Immunicum, for the treatment of cancer. The vaccine, called INTUVAX®, Immunicum AB (publ), First North Premier: (IMMU.ST), ett bioteknikbolag som utvecklar nya immunaktiverande cancerbehandlingar för ett antal solida tumörer, meddelar i dag att bolaget har erhållit godkännande av det internationella generiska namnet (INN), ilixadencel för sin ledande läkemedelskandidat INTUVAX®, en cancerimmunaktiverare speciellt utvecklad för att förstärka … 2020-08-18 Immunicum AB (publ; IMMU.ST) meddelar idag prekliniska data som stöder kombinationen av ilixadencel, en cellbaserad lagringsbar immunaktiverare, med cancerbehandlingar och immunterapier inklusive anti-VEGF, anti-PD1 och anti-CTLA4 under en posterpresentation på årets ESMO-kongress (ESMO Virtual Congress 2020). Immunicum AB (publ) announced today an update on survival data from the randomized Phase II MERECA trial evaluating its off-the-shelf immune primer, ilixadencel, in combination with Sutent (sunitinib) first-line treatment regimen in newly diagnosed patients with metastatic renal cell carcinoma (mRCC).. During the trial, 88 patients were randomly assigned in a two-to-one ratio to the Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC) Immunicum AB (publ; IMMU.ST) announced today that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the Company’s lead candidate, ilixadencel, a cell-based, off-the-shelf immune primer, for the treatment of … 2020-05-06 For Immunicum, 2019 was a year of important clinical advancements with their lead candidate, ilixadencel. It demonstrated promising potential in both the MERECA and the GIST studies from which topline results were announced. These advancements were the main focus of the year-end report released last week.

Immunicum AB (publ) today announced updated survival data from the Company’s randomized Phase II MERECA trial evaluating its off-the-shelf immune primer, ilixadencel, in combination with

Bolaget med vd Carlo de Sousa i spetsen ser fram emot att under året ytterligare validera potentialen hos läkemedelskandidaten. Trots tydliga tecken på framsteg inom onkologifältet är cancer fortfarande högt på listan av sjukdomar som människor världen över 2020-12-31 Immunicum has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel. Ilixadencel is a cell-based, off-the-shelf immune primer, for the treatment of Soft Tissue Sarcoma (STS).

Immunicum AB (publ; IMMU.ST) announced today that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the Company’s lead

BioStock caught up with the company’s interim CEO, Alex […] In today’s Sunday Interview we talk to Carlos de Sousa, CEO of Immunicum. He shares his thoughts on why lead drug candidate ilixadencel may be the next generation of immuno-oncology therapies, on negotiating with two of the world’s biggest pharma companies and on what made some of Sweden’s top institutional investors, including hedge fund giant Max Mitteregger, commit […] Immunicum erhöll särläkemedelsstatus, Orphan Drug Designation, från FDA för ilixadencel för behandling av levercancer, specifikt hepatocellular carcinoma (HCC). COVID-19. Immunicum har hittills inte haft någon väsentlig påverkan på verksamheten på grund av covid-19-pandemin. För mer information se riskavsnittet sid 12 i Pressmeddelande 17 augusti 2017 Immunicum slutför sin strategiska analys och uppdaterar den kliniska utvecklingsplanen för ilixadencel Immunicum AB (publ), Firs 2021-02-19 Find the latest Immunicum AB (IMMU.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Immunicum is a clinical-stage immunoncology company based in Stockholm, Sweden. It is developing an allogeneic off-the-shelf dendritic cell immune activator or immune primer, ilixadencel, for use in combination with checkpoint inhibitors and other anti-cancer therapies in potentially any solid tumour indications accessible via direct injection.

Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel Immunicum is listed on NASDAQ Stockholm under the ticker IMMU Tweets by @Immunicum Press Release 26 January 2021 Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma (STS) Immunicum AB (publ; IMMU.ST) announced today that Immunicum AB (publ; IMMU.ST) announced today that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the Company’s lead About ilixadencelIlixadencel is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived In December 2020, Immunicum announced that it received Fast Track Designation from the FDA for ilixadencel in Gastrointestinal Stromal Tumors (GIST) and Orphan Drug Designation by the FDA for ilixadencel in hepatocellular carcinomas. In January of this year, the company announced FDA Orphan Drug Designation for ilixadencel in STS. Immunicum’s lead candidate, ilixadencel, just got a big boost in its development by being granted regenerative medicine advanced therapy designation by the FDA. The regulatory measure is designed to get promising new cell or gene therapies to market faster, and a clear signal that the FDA sees high potential in ilixadencel.
Apotea matvaror

The company most recently presented comprehensive pre-clinical results showing that this transformation leads to an immunogenic shift. In May 2020, Immunicum received Regenerative Medicine Advanced Therapy designation from the FDA for ilixadencel for the treatment of patients with metastatic Renal Cell Carcinoma.

Immunicum is a clinical-stage immunoncology (IO) company based in Stockholm, Sweden.
Fördelar med djurförsök

Ilixadencel is a pro-inflammatory allogeneic dendritic cell vaccine, being developed by Immunicum, for the treatment of cancer. The vaccine, called INTUVAX®,

Published Immunicum: MERECA Update Confirms Ilixadencel Benefit. 4 Feb 2020 15Background: Ilixadencel is a cell-based, off-the-shelf product based on allogeneic monocyte-derived Immunicum AB, Stockholm, Sweden. 10 Feb 2020 According to their website, Ilixadencel, Immunicum AB's lead development candidate, is an off-the-shelf cell-based cancer immunotherapy Immunicum – del av Sveriges långsiktiga satsning på ATMP. 2 feb 2021. EVELYN PESIKAN, ilixadencel, Immunicum, MERECA. ATMP (Advanced Therapy 21 Dec 2020 Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney Pressmeddelande 31 december 2020 Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel för behandling av Pressmeddelande 7 december 2020 Immunicum AB (publ) erhåller Fast Track Designation från FDA för ilixadencel för behandling av GIST In addition to ilixadencel, these applications will allow the company to pursue or benefit from leading immuno-oncology trends in the biopharmaceutical industry.

We look forward to start enrolling patients in that trial this year," said Carlos de Sousa, CEO of Immunicum. "Ilixadencel has broad potential as a

PMID: 29904904 PMCID: PMC6002422 DOI: 10.1007/s11095-018-2438-x Abstract 2020-09-17 To date Immunicum has established clinical proof of concept for its lead program, ilixadencel, which has been tested in a range of solid tumors. DCprime has produced equally encouraging clinical results for blood-borne tumors including interim data from its ongoing Phase II … Immunicum has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the company’s lead candidate, ilixadencel.

These advancements were the main focus of the year-end report released last week. BioStock caught up with the company’s interim CEO, Alex […] In today’s Sunday Interview we talk to Carlos de Sousa, CEO of Immunicum. He shares his thoughts on why lead drug candidate ilixadencel may be the next generation of immuno-oncology therapies, on negotiating with two of the world’s biggest pharma companies and on what made some of Sweden’s top institutional investors, including hedge fund giant Max Mitteregger, commit […] Immunicum erhöll särläkemedelsstatus, Orphan Drug Designation, från FDA för ilixadencel för behandling av levercancer, specifikt hepatocellular carcinoma (HCC). COVID-19. Immunicum har hittills inte haft någon väsentlig påverkan på verksamheten på grund av covid-19-pandemin. För mer information se riskavsnittet sid 12 i Pressmeddelande 17 augusti 2017 Immunicum slutför sin strategiska analys och uppdaterar den kliniska utvecklingsplanen för ilixadencel Immunicum AB (publ), Firs 2021-02-19 Find the latest Immunicum AB (IMMU.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Immunicum is a clinical-stage immunoncology company based in Stockholm, Sweden.